Agrylin
Agrylin Brand names, Agrylin Analogs
Agrylin Brand Names Mixture
- No information avaliable
Agrylin Chemical_Formula
C10H7Cl2N3O
Agrylin RX_link
http://www.rxlist.com/cgi/generic/anagrel.htm
Agrylin fda sheet
Agrylin msds (material safety sheet)
Agrylin Synthesis Reference
No information avaliable
Agrylin Molecular Weight
256.088 g/mol
Agrylin Melting Point
280 oC
Agrylin H2O Solubility
Very slightly soluble
Agrylin State
Solid
Agrylin LogP
2.333
Agrylin Dosage Forms
Capsules (0.5 mg or 1 mg)
Agrylin Indication
For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
Agrylin Pharmacology
Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 = 36nM) inhibitor of phosphodiesterase-III.
Agrylin Absorption
No information avaliable
Agrylin side effects and Toxicity
There are no reports of overdosage with anagrelide, however thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Single oral doses of anagrelide at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys.
Agrylin Patient Information
Agrylin Organisms Affected
Humans and other mammals
